Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | BTN3A1 | O00481 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ENO1 | P06733 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153172 | 0.84 | PRKCA (0.38) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL681950 | 0.78 | PRKCA (0.46) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL5534787 | 0.74 | PRKCA (0.43) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL27999368 | 0.74 | PRKCA (0.43) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL8893353 | 0.73 | PRKCA (0.39) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL434232 | 0.72 | PRKCA (0.42) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL807413 | 0.72 | PRKCA (0.42) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL15472935 | 0.72 | PRKCA (0.42) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL8716409 | 0.70 | PRKCA (0.41) | PRKCAPOLBGAANPSR1BTN3A1 | |
| SCHEMBL6840326 | 0.70 | ALDH1A1 (0.42) | PRKCAPOLBGAANPSR1BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-6734205-B2 | SODIUM CHANNEL MODERATORS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2004-05-11 | — | — | US | disclosed |
| US-20030018056-A1 | Substituted guanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1238971-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018056-A1 | Substituted guanidine derivatives | SLC28A1, SLC7A1, ABCB11 | PRKCA 4311/4885POLB 1536/4885GAA 292/4885 |
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | PRKCA 264/4885POLB 4155/4885GAA 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.